1 / 8

Strategic Overview of Zytas and Flovista Products and Objectives

This document highlights the current situation for Dekapharma regarding its key products, Zytas and Flovista. Our research and development (R&D) team has set a target growth rate of 12%, with specific goals of 3% growth for Zytas and increased market presence for Flovista. The budget allocated for executing our strategies is $23,450, which outlines the necessary support for our essential initiatives. We appreciate your ongoing support and commitment to achieving these objectives.

ulric-franklin
Télécharger la présentation

Strategic Overview of Zytas and Flovista Products and Objectives

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DEKAPHARMA

  2. ituation actuelle S

  3. roduits (Zytas, flovista) P P roduits

  4. R & D C lients

  5. O bjectifs 12% Zytas 3% Flovista S tratégie olution

  6. S Ystème des M embres I mportants

  7. B udget T otal 23 450$

  8. ! Merci

More Related